Cronos Group (TSE:CRON) Stock Price Down 2.8% - Here's What Happened

Key Points

• Cronos Group stock fell 2.8% intraday to C$3.50 on Tuesday, with 86,135 shares traded — about 46% below the average session volume.
• Analysts remain positive, with two recent "Buy" ratings (Canaccord C$4.25, TD Securities C$4.50) and an average price target of C$4.38.
• Cronos has a market cap of C$1.33 billion, a negative PE (-175), low leverage (debt-to-equity 0.25) and very high liquidity ratios (current ratio 19.59, quick ratio 24.01), indicating strong short-term liquidity despite unprofitable earnings.

Cronos Group Inc. (TSE:CRON - Get Free Report)'s share price fell 2.8% during mid-day trading on Tuesday . The stock traded as low as C$3.50 and last traded at C$3.50. 86,135 shares changed hands during trading, a decline of 46% from the average session volume of 160,366 shares. The stock had previously closed at C$3.60.

Analysts Set New Price Targets

Several brokerages recently issued reports on CRON. Canaccord Genuity Group set a C$4.25 target price on shares of Cronos Group and gave the stock a "buy" rating in a report on Tuesday, January 27th. TD Securities set a C$4.50 price objective on shares of Cronos Group and gave the company a "buy" rating in a report on Tuesday, February 24th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Cronos Group currently has an average rating of "Buy" and an average price target of C$4.38.

Cronos Group Stock Down 2.8%

The company has a debt-to-equity ratio of 0.25, a current ratio of 19.59 and a quick ratio of 24.01. The business's fifty day simple moving average is C$3.54 and its two-hundred day simple moving average is C$3.60. The company has a market cap of C$1.33 billion, a PE ratio of -175.00, a PEG ratio of 0.12 and a beta of 1.04.

About Cronos Group

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.